Analyst Research

Report Title Price
Koninklijke DSM NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
$20.00
Buy
ValuEngine Detailed Valuation Report for RDSMY
Provider: ValuEngine, Inc.
$127.00
Buy
Wright Investors Service Comprehensive Report for Koninklijke DSM N.V.
Provider: Wright Reports
$483.00
Buy
Koninklijke DSM NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
$20.00
Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Koninklijke DSM NV Announces FY 2013 Outlook; Proposes FY 2013 Dividend


Tuesday, 19 Feb 2013 07:00pm EST 

Koninklijke DSM NV announced that for fiscal year 2013 it expects to move towards Earnings Before Interest and Taxes, Depreciation and Amortization (EBITDA) of EUR 1.4 million. The Company also proposed a fiscal year 2013 dividend of EUR 1.50 per share. 

Latest Developments for Koninklijke DSM NV

Latest Key Developments in Chemicals

Company Quote

Koninklijke DSM NV
(RDSMY.PK)
15.81
0.09 +0.57%
17 May 2013